ESR1 and breast carcinoma: While the former is associated with severe side effects, including venous thromboembolic disorders, breast cancer, endometrial cancer, and cortical porosity in cases of selective estrogen receptor (ER) modulators [8,9,10], the efficacy of the latter is uncertain.